Source:

Korn S, et al. Clinical trials in airway diseases: Novel treatments and new evidence. Presented at: European Respiratory Society International Congress; Sept. 5-8, 2021 (virtual meeting).

Disclosures: Korn reports receiving honoraria or consultant fees from AstraZeneca, GlaxoSmithKline, Novartis, Roche, Sanofi Aventis and Teva.
September 22, 2021
2 min read
Save

Tezepelumab increases proportion of patients free from exacerbations

Source:

Korn S, et al. Clinical trials in airway diseases: Novel treatments and new evidence. Presented at: European Respiratory Society International Congress; Sept. 5-8, 2021 (virtual meeting).

Disclosures: Korn reports receiving honoraria or consultant fees from AstraZeneca, GlaxoSmithKline, Novartis, Roche, Sanofi Aventis and Teva.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Tezepelumab increased the proportion of exacerbation-free patients with severe, uncontrolled asthma compared with placebo, even among those with three or more exacerbations within the previous year.

Results from the prespecified exploratory analysis of the NAVIGATOR trial were presented at the virtual European Respiratory Society International Congress.

Asthma Blocks
Source: Adobe Stock.

“Tezepelumab increased the proportion of exacerbation-free patients vs. placebo among those with two exacerbations in the prior year, but also in patients with even more exacerbations,” Stephanie Korn, MD, senior physician in pneumology and respiratory medicine at IKF Pneumologie Mainz and Thoraxklinik Ambulanz and Heidelberg, Germany, said during a presentation. ... “These data provide further evidence of the potential benefits of tezepelumab in patients with severe, uncontrolled asthma.”

Healio previously reported results from the NAVIGATOR study, a phase 3, multicenter, randomized, double-blind, placebo-controlled study, in which tezepelumab (Amgen/AstraZeneca) demonstrated a reduction in asthma exacerbations among patients with severe asthma and a broad range of inflammatory profiles.

The new prespecified exploratory analysis included 1,059 patients aged 12 to 80 years (mean age, 49.5 years; 36.5% men) with severe, uncontrolled asthma. All patients received either medium- or high-dose inhaled corticosteroids and one or more additional controller medication with or without oral corticosteroids. Patients were randomly assigned to receive subcutaneous tezepelumab 210 mg (n = 528) or placebo (n = 531) every 4 weeks for 52 weeks.

Researchers assessed the proportion of exacerbation-free patients in the overall population and the proportion of exacerbation-free patients when categorized by asthma exacerbations experienced within the past year (two, n = 635; three, n = 424).

The proportion of exacerbation-free patients was higher among those assigned tezepelumab compared with placebo in the overall population (54.2% vs. 38.6%; OR = 1.93; 95% CI, 1.51-2.47), according to Korn.

In addition, higher proportions of exacerbation-free patients were observed with tezepelumab vs. placebo among those with two asthma exacerbations in the previous year (56.5% vs. 44.6%; OR = 1.61; 95% CI, 1.17-2.21) and in those with three or more asthma exacerbations (50.9% vs. 29.1%; OR = 2.58; 95% CI, 1.72-3.86) in the previous year, Korn said.

Researchers also observed an improvement in prebronchodilator FEV1 at 52 weeks among exacerbation-free patients assigned tezepelumab compared with placebo irrespective of the number of prior exacerbations (two prior exacerbations: change, 0.26 vs. 0.14; 95% CI, 0.03-0.22; three prior exacerbations: change, 0.3 vs. 0.09; 95% CI, 0.08-0.35).